Smith J D, Sindhi R, Rogers R, Lazarchick J
Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston 29425, USA.
Ann Clin Lab Sci. 1998 Sep-Oct;28(5):280-2.
The development of a high-titer factor V inhibitor is described in a patient who underwent orthotopic liver transplantation followed by porcine xenoperfusion after an acute rejection episode. The inhibitor showed no cross-reactivity to either porcine or bovine factor V, nor was it accessible to human platelet factor V. The limitations of treatment modalities including intravenous immunoglobulin, steroids, cytotoxic therapy, intense plasmapheresis and platelet transfusions are discussed.
本文描述了一名接受原位肝移植的患者在急性排斥反应后进行猪异种灌注后，出现高滴度因子V抑制剂的情况。该抑制剂对猪或牛因子V均无交叉反应，人血小板因子V也无法与之结合。文中还讨论了包括静脉注射免疫球蛋白、类固醇、细胞毒性疗法、强化血浆置换和血小板输注在内的治疗方式的局限性。
